Last reviewed · How we verify
NCT04161768
Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Phase 3 trial testing Norfloxacin in Spontaneous Bacterial Peritonitis in 80 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 1 December 2018 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Norfloxacin (NORFLOXACIN) — full drug profile →
- Itopride (ITOPRIDE) — full drug profile →
Conditions studied
- Spontaneous Bacterial Peritonitis — all drugs for Spontaneous Bacterial Peritonitis →
Sponsor
Tanta University
Who can join
Eligibility, any sex, with Spontaneous Bacterial Peritonitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04161768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Norfloxacin
Trials testing the same drug.
- NCT06199843 — Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial) · NA · unknown
- NCT04159870 — Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis · Phase 3 · unknown
- NCT03702426 — Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Pro · NA · completed
Other recruiting trials for Spontaneous Bacterial Peritonitis
Currently open trials in the same condition.
- NCT06026267 — Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontan · NA · recruiting
- NCT04168099 — Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis · Phase 3 · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04161768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 13 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04161768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing